BDBM50101761 (S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcarbamoyl)-ethyl]-thiophene-2-carbonyl}-amino)-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid::CHEMBL302395

SMILES Cc1cc(C)c(c(C)c1)S(=O)(=O)N[C@@H](CNC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)C(O)=O

InChI Key InChIKey=VCYXSHVQNGNXQO-UHFFFAOYSA-N

Data  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 50101761   

TargetIntegrin alpha-IIb/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)
Affinity DataIC50: 11nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta-3 integrin by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor (Vn/293) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed